Video Experimental Relacionado
Updated: May 11, 2026
06:06
In Vitro Analysis of E3 Ubiquitin Ligase Function
Published on: May 14, 2021
La estructura de parkin revela los mecanismos para la activación de la ubiquitina ligasa
Jean-François Trempe1, Véronique Sauvé, Karl Grenier
1McGill Parkinson Program, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montréal, Québec, Canada.
Science (New York, N.Y.)
|May 11, 2013
Resumen
Los investigadores aclararon la estructura de la proteína parkin, revelando su estado autoinhibido. Comprender este mecanismo de activación de parkin ofrece una vía para mejorar sus funciones neuroprotectoras en la enfermedad de Parkinson.
Área de la Ciencia:
- La neurociencia es la neurociencia.
- Biología Estructural Biología estructural.
- Genética La genética.
Sus antecedentes:
- Las mutaciones en el gen PARK2 causan la enfermedad de Parkinson autosómica recesiva.
- La proteína parkin, una ligasa de ubiquitina E3, tiene una baja actividad basal.
- Parkin juega un papel crucial en la salud neuronal y es neuroprotector.
Objetivo del estudio:
- Para determinar la estructura cristalina de parquín de ratas de cuerpo entero.
- Aclarar las bases estructurales de los mecanismos de autoinhibición y activación de Parkinson.
- Proporcionar un marco para el desarrollo de estrategias para mejorar la actividad de parkin.
Principales métodos:
- Cristalografía de rayos X para obtener la estructura de parquín de rata de longitud completa.
- Ensayos bioquímicos para evaluar la actividad de parkin in vitro.
- Pruebas basadas en células para evaluar los efectos de las mutaciones en la función de Parkin.
Principales resultados:
- La estructura cristalina reveló a Parkin en una conformación autoinhibida.
- Se encontró que RING0 ocluye el sitio de aceptor de ubiquitina en RING2.
- Se observó que un elemento represor se une a RING1, bloqueando el sitio de unión E2.
- Las mutaciones que interrumpen estas interacciones inhibidoras llevaron a la activación de parkin in vitro y en las células.
Conclusiones:
- El estudio proporciona los primeros conocimientos estructurales sobre la autoinhibición y activación de la parkin E3 ubiquitin ligasa.
- Comprender estos mecanismos es crucial para desarrollar estrategias terapéuticas dirigidas a la enfermedad de Parkinson.
- Los hallazgos ofrecen una base estructural y mecanicista para mejorar la actividad neuroprotectora de Parkinson.
Videos de Conceptos Relacionados
02:04Covalently Linked Protein Regulators
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
These groups modify specific amino acids in a protein.
02:58Regulated Protein Degradation
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
01:17The Proteasome Structure
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
01:13The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
02:18The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...